In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Current Strategies in Managing Obesity STRIVE Obesity What Is BPC 157? A Medical Clinic's Guide to the Body Protective Peptide, Its Uses, and What It Actually Does Perfect B The next frontier in metabolic health: Cagrilintide Semaglutide and the evolving landscape of therapies Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late Stage Trial: Novo Nordisk Update Patient Care Online Peptide BPC 157 Does It Work? Breaking Down the Evidence and the Hype